Applied Therapeutics (APLT)
(Real Time Quote from BATS)
$4.48 USD
+0.02 (0.45%)
Updated Apr 23, 2024 03:26 PM ET
2-Buy of 5 2
F Value D Growth B Momentum F VGM
Price, Consensus and EPS Surprise
APLT 4.48 +0.02(0.45%)
Will APLT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for APLT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for APLT
Applied Therapeutics (APLT) Surges 124% in a Month: Here's Why
Bears are Losing Control Over Applied Therapeutics Inc. (APLT), Here's Why It's a 'Buy' Now
APLT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Dr. Reddy's (RDY) Q4 Earnings Decline Y/Y, Sales Increase
Alnylam's (ALNY) Marketed Drugs Aid Growth Amid Competition
Ultragenyx (RARE) Acquires Rights of AAV Gene Therapy Candidate
Other News for APLT
Simplify Propel Opportunities ETF: Healthcare Likely To Rise Again In FY24 And Beyond
Applied Therapeutics Appoints Dale Hooks as Chief Commercial Officer
Applied Therapeutics appoints Dale Hooks as CCO
Applied Therapeutics Welcomes Dale Hooks as New CCO
RBC Capital Sticks to Their Buy Rating for Applied Therapeutics (APLT)